Company Overview of Dezima Pharma B.V.
Dezima Pharma B.V. develops protein-based compounds for treatment of cardiovascular disease related to dyslipidemia. The company was founded in 2012 and is based in Naarden, the Netherlands.
Naarden, 1411 DC
Founded in 2012
31 35 699 3000
31 35 699 3001
Key Executives for Dezima Pharma B.V.
Founder and Chairman of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
Dezima Pharma B.V. Key Developments
Dezima Pharma B.V. Announces Complete Enrolment of CETP Inhibitor TA-8995 Study in Subjects with Isolated, Elevated Lipoprotein(a) Levels
Nov 13 14
Dezima Pharma B.V. announced the complete enrolment of a study with TA-8995 in asymptomatic subjects with isolated, severely elevated Lipoprotein(a) (Lp(a)), which was initiated in September of 2014. The aim of this study, that enrolled 42 male and female subjects from the Copenhagen General Population Study database, is to investigate the Lp(a) lowering effects of TA-8995 (DEZ-001), a best-in-class CETP inhibitor. The subjects have been randomised to one of two different doses of TA-8995 or placebo and will be treated for 12 weeks. The Lp(a) pilot study is being conducted at the Herlev Hospital, Copenhagen University Hospital in Denmark. Lp(a) is an independent major risk factor for cardiovascular disease and aortic valve stenosis. In previous phase 1 studies in healthy volunteers with normal baseline Lp(a) levels, as well as in the phase 2b TULIP study, TA-8995 has shown a potent effect on Lp(a) plasma levels.
Dezima Pharma Reports Positive Results in its Phase 2b TULIP Trial with CETP Inhibitor TA-8995 in Dyslipidemia
Aug 29 14
Dezima Pharma announced that it has received very positive results in its Phase 2b TULIP clinical trial, a double blind, placebo controlled, Phase 2b dose ranging study of TA-8995 (DEZ-001), as monotherapy and in combination with statins for treating dyslipidemia. The TULIP (TA-8995: its Use in patients with mild dysLIPidemia) study was conducted in specialized cardiovascular centres across Denmark and the Netherlands. A total of 364 patients were randomised into nine cohorts; a placebo, TA-8995 alone at different doses, or in combination with different statins. The study investigated the effects of TA-8995 on a wide range of established cardiovascular disease (CVD) biomarkers over a three months' dosing period. The results showed dramatic effects on the primary endpoint, which was a composite of changes in lowering LDL-C and raising HDL-C, as well as strong and clinically relevant effects on other parameters including cholesterol efflux and Lipoprotein(a) (Lp(a)). There were no safety or tolerability issues identified or any pharmacokinetic concerns about potential accumulation of the drug.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 16, 2015
Most Searched Private Companies
Sponsored Financial Commentaries